City of Hope
1500 E Duarte Rd
About City of Hope
City of Hope, an innovative biomedical research, treatment and educational institution with over 5,000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy.
Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s 20 leading cancer centers that develops and institutes standards of care for cancer treatment.
Individually we are many things. Together, we are hope.
91 articles with City of Hope
City of Hope Comprehensive Cancer Center earns highest ranking from National Cancer Institute
City of Hope announced that its comprehensive cancer center has received the highest rating possible for a U.S. cancer center — "exceptional" — by the National Cancer Institute, the federal government's principal agency for cancer research and training.
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that its subsidiary, Cancer Treatment Centers of America®, will fully transition its clinical locations to City of Hope's brand.
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute, part of City of Hope, announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma, a rare and often fatal childhood cancer.
Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer
Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health; the Translational Genomics Research Institute, part of City of Hope, a nonprofit biomedical research center; and OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, announced a new research study.
City of Hope-led trial leads to U.S. Food and Drug Administration's approval of a first of its kind bispecific antibody
A trial led by City of Hope, one of the largest cancer research and treatment organizations in the nation, contributed to the U.S. Food and Drug Administration's approval of mosunetuzumab, the first bispecific antibody to treat people with relapsed or difficult to treat follicular lymphoma, a type of non-Hodgkin lymphoma, after they have received two or more standard therapies.
City of Hope Study Finds That Neuroendocrine Cancer Patients and Doctors Agree on Treatment Goals Only Half of the Time
A new study by researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, reveals that people with neuroendocrine cancer overwhelmingly prioritize quality of life over living longer.
City of Hope shares in $8 million Prostate Cancer Foundation award to develop CAR T cell therapy for advanced prostate cancer
City of Hope announced it has received, along with other leading cancer centers, an $8 million Therapy ACceleration To Intercept CAncer Lethality award from the Prostate Cancer Foundation to develop clinic-ready chimeric antigen receptor T cell therapies for advanced prostate cancer that can overcome the therapy's current limitations.
City of Hope scientists develop new potential treatment for brain tumors
Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be difficult to reach with surgery and other treatments.
City of Hope Study Finds Medicare Advantage May Put Complex Cancer Surgery Patients at a Disadvantage
An analysis by researchers at City of Hope found that cancer patients with privatized, cost-saving Medicare Advantage were more likely than those with traditional Medicare to go to hospitals with physicians less experienced at performing complicated surgeries, and that they were more likely to die within the first 30 days after the removal of their stomach, pancreas or liver.
Alberto Pugliese, M.D., Joins City of Hope as Director of The Wanek Family Project for Type 1 Diabetes and Chair of the Department of Diabetes Immunology
Alberto Pugliese, M.D., has joined City of Hope as the Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute.
Raven-Symone Pearman-Maday to host inaugural Halloween for Hope organized by new City of Hope Junior Board
City of Hope, one of the largest cancer research and treatment organizations in the U.S., is proud to announce the inaugural Halloween for Hope, an event presented by the organization's new Junior Board, featuring a soiree full of tricks and treats designed to enchant the entire family.
City of Hope to Accelerate Immunotherapy Research and Treatment Innovation With $15 Million Gift From Ted Schwartz Family
City of Hope announced a $15 million gift from City of Hope patient and cancer survivor Ted Schwartz that will be used entirely to further accelerate immunotherapy research and treatment innovations, such as the chimeric antigen receptor T cell therapy that saved his life.
Endocrine Therapy Before Surgery Results in Different Outcomes in Black vs. White Women With Breast Cancer, City of Hope-Led Study Finds
A study led by City of Hope, one of the largest cancer research and treatment organizations in the United States, found that Black women with Stage 1 or 2 breast cancer were almost three times more likely than white women to have tumor shrinkage from hormone therapy delivered prior to surgery, yet Black women were more likely than their white counterparts to have worse outcomes when this type of endocrine therapy before surgery was used at a later stage of disease.
City of Hope and FivePoint Invite Orange County, Calif. Residents to Rise Above Cancer as Great Park Balloon Soars with Messages of Hope
City of Hope, one of the largest cancer research and treatment organizations in the United States, is sending the iconic Great Park Balloon in Irvine, California, into the sky with a message of hope for ending the disease that affects 1 in 3 Americans in their lifetime.
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma
Calidi Biotherapeutics, Inc. is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a phase 1 physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7.
World Lung Cancer Day: City of Hope Approved for $7 Million to Study Interventions for Lung Cancer in Older Adults
City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that it has been approved for nearly $7 million from the Patient-Centered Outcomes Research Institute to study how physical activity affects older adults undergoing lung cancer surgery.
CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer
CytoImmune Therapeutics and City of Hope today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CYTO-102.
City of Hope revealed that the oldest person living with HIV has achieved clinical remission after undergoing stem cell transplantation at the center more than three years ago.
City of Hope Opens the Most Advanced Comprehensive Cancer Center in Orange County, Calif., Delivering World-Renowned Treatment, Research and Cancer Cures to the Nation’s Sixth Largest County
City of Hope, one of the largest cancer research and treatment organizations in the United States, opens its visionary comprehensive cancer center in Orange County, California, creating a national model for delivering breakthrough research and pioneering treatments.